このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

Balance4mobility:末梢神経障害とバランスの問題を抱える個人におけるワークアシンの使用の影響

2026年10月2日 更新者:RxFunction Inc.

Balance4mobility:末梢神経障害とバランスの問題を抱える個人における歩行とバランス機能の臨床結果に対するワークアシンの使用の影響 - 無作為化対照試験

The goal of this clinical trial is to is to test whether Walkasins can help people with peripheral neuropathy maintain their balance better. The main question it aims to answer is whether participants who use Walkasins on an everyday basis over a six-month period will report better awareness of their foot placement on the ground.

Researchers will compare Walkasins users to a control group of participants who are not using Walkasins to see if the device improves the users' performance on some standing and walking tests. Control group participants will get Walkasins after six months of being in the study.

During the study participants will be asked to do the following:

  • Answer questions about their medical history and balance.
  • Do some standing and walking tests. Some of the tests will be timed.
  • Attend study visits and participate in study phone calls.
  • Keep track of any falls and notify study staff if they fall.
  • Wear the Walkasins device on a regular basis.

調査の概要

詳細な説明

A randomized cross-over study of short-term, in-clinic effects of Walkasins use, conducted at the Minneapolis Veterans Affairs Medical Center (VAMC) and published in PLOS ONE, found clinically meaningful and statistically significant improvements in gait speed and functional balance in patients with SPN using Walkasins. The authors stated that "findings suggest new sensory balance cues provided to the lower limb can modulate the activity of relevant nerve afferents and become integrated into sensorimotor control of balance and gait."

In 2020 a multi-site clinical trial of the long-term effects of daily Walkasins use (walk2Wellness, ClinicalTrials.gov #NCT03538756) was published in Frontiers in Aging Neuroscience. After 10 weeks of Walkasins use, this long-term study demonstrated clinically meaningful improvements in Functional Gait Assessment (FGA) and gait speed, which is associated with a lower fall risk. The authors concluded that "a wearable sensory prosthesis may provide a new way to treat gait and balance problems and manage falls in high fall-risk patients with PN."

Most recently, an analysis of data from 26 weeks of Walkasins use in the walk2Wellness trial showed that "participants who reported falls over 6 months prior to the study had a 43% decrease in fall rate during the study as compared to self-report 6-month pre-study (11.8 vs. 6.7 falls/1000 patient days, respectively, p <0.004), similar to the 46% decrease reported after 10 weeks of use."

The present study involves an assessment of Walkasins through a randomized, controlled trial with a primary endpoint of 26 weeks. Furthermore, this study will enroll only individuals 55 and older with a goal of including participants that reflect the Medicare population to support payer reimbursement for Walkasins.

The objectives of this study are as follows:

  • Reflect real-world use of Walkasins in a Medicare-representative population who have sensory peripheral neuropathy and associated gait and balance problems and who would be eligible for a prescription to use the device.
  • Investigate the impact of Walkasins use on relevant clinical outcomes associated with gait and physical function.
  • Demonstrate based on patient reporting that Walkasins improves awareness of foot placement on the ground indicating partial replacement of plantar mechanoreceptor function, lost due to peripheral neuropathy.
  • Investigate whether plantar monofilament testing at levels <10g (5.07, LOPS) are associated with gait and balance issues. Is there a Loss Of Balance Sensation (LOBS) threshold that is <10g? The monofilament test protocol should include plantar sites across the foot since differences in anteroposterior and/or mediolateral sensitivity may cause balance issues.
  • Compare the rate of injurious falls between a group of Walkasins users and non-users over a six-month period.

研究の種類

介入

入学 (推定)

200

段階

  • 適用できない

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究連絡先

研究連絡先のバックアップ

研究場所

    • Arizona
      • Mesa、Arizona、アメリカ、85206
        • 積極的、募集していない
        • OrthoArizona--Mesa Arbor Avenue
    • Massachusetts
      • Boston、Massachusetts、アメリカ、02131
        • 積極的、募集していない
        • Marcus Institute for Aging Research, Hebrew SeniorLife
    • Minnesota
      • Saint Paul、Minnesota、アメリカ、55102
    • New York
      • Amherst、New York、アメリカ、14226
        • 募集
        • Dent Neurologic Institute
        • 主任研究者:
          • Lixin Zhang, MD, PhD
        • コンタクト:
        • コンタクト:
    • Pennsylvania
      • Pittsburgh、Pennsylvania、アメリカ、15206
        • 募集
        • University of Pittsburgh
        • コンタクト:
        • コンタクト:
          • Julie Faieta, PhD
          • 電話番号:412-624-8575
          • メール:JUF52@pitt.edu
    • Texas
      • Galveston、Texas、アメリカ、77555
        • 募集
        • University of Texas Medical Branch
        • コンタクト:
          • Gregory Brusola, PhD, DPT, PT
          • 電話番号:409-772-0309
          • メール:gabrusol@utmb.edu
        • コンタクト:
        • 主任研究者:
          • Gregory Brusola, PhD, DPT, PT

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

55年歳以上 (大人、高齢者)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

説明

Inclusion Criteria:

  • Able to understand and provide informed consent for him or herself
  • Age 55 and older, male or female
  • Able to complete all functional outcome measures without the use of an assistive device
  • Clinical diagnosis of peripheral neuropathy prior to participating in the study as documented in the participant's medical record or by physician's note. Individuals with chemo-induced peripheral neuropathy must be at least one-year post-chemotherapy, indicating that their PN has become a chronic condition.
  • Self-reported gait and balance problems
  • Foot size that allows the Walkasins to function appropriately
  • Willing to use the Walkasins device as recommended

Exclusion Criteria:

  • Ability to stand on one leg for at least 30 seconds (If the person can stand for at least 30 seconds, he/she is excluded because his/her balance is likely not impaired enough to benefit from Walkasins.)
  • Self-reported acute thrombophlebitis, including deep vein thrombosis
  • Self-reported severe peripheral vascular disease
  • Untreated lymphedema
  • Untreated lesion of any kind, swelling, infection, inflamed area of skin or eruptions on the lower leg near product use
  • Self-reported, untreated fractures in the foot and ankle
  • Other neurological or musculoskeletal conditions that moderately or severely impact walking
  • Use of ankle-foot orthosis for ambulation that prevents donning of Walkasins
  • Weight of more than 300 pounds
  • Inability to perceive vibration from Walkasins Haptic Module

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:処理
  • 割り当て:ランダム化
  • 介入モデル:並列代入
  • マスキング:なし(オープンラベル)

武器と介入

参加者グループ / アーム
介入・治療
実験的:Walkasins User Group

Participants randomized to the user group will receive Walkasins, consisting of two parts for each leg: the Haptic Module and the Receptor Sole. They will use the device for one year (52 weeks). In addition, the user group participants will receive the fall prevention information provided to the control group.

Walkasins® is an external, lower limb sensory prosthesis intended to replace part of the nerve function used for detection and signaling of foot pressure sensation during standing and walking activities. Walkasins consist of two parts for each leg: the Haptic Module and the Receptor Sole. The Haptic Module wraps around the lower leg of the user and contains electronics for reading Receptor Sole pressure signals, a microprocessor, and four vibrating motors that provide gentle tactile sensory cues to the front, back, medial, and lateral surfaces of the user's leg. These cues reflect real-time foot pressure information at a location above the ankle where skin sensation is still present.

Participants will watch "6 Steps to Prevent a Fall," a short (2 minute) educational video from the National Council on Aging, which describes simple steps to reduce fall risk. To improve their access to the education provided, participants will also receive three handouts, produced by the Center for Disease Control and Prevention (CDC) STEADI initiative (Stopping Elderly Accidents, Deaths, and Injuries), to review after the study visit. The STEADI Initiative is a coordinated approach for healthcare providers to implement the American and British Geriatrics Societies' Clinical Practice Guideline for fall prevention (https://www.cdc.gov/steadi/index.html).

他の:Control Group

Participants randomized to the control group will receive fall prevention information during the baseline visit. After six months, they will receive Walkasins for use during the final six months of the trial.

Participants will watch "6 Steps to Prevent a Fall," a short (2 minute) educational video from the National Council on Aging, which describes simple steps to reduce fall risk. To improve their access to the education provided, participants will also receive three handouts, produced by the Center for Disease Control and Prevention (CDC) STEADI initiative (Stopping Elderly Accidents, Deaths, and Injuries), to review after the study visit. The STEADI Initiative is a coordinated approach for healthcare providers to implement the American and British Geriatrics Societies' Clinical Practice Guideline for fall prevention (https://www.cdc.gov/steadi/index.html).

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Functional Gait Assessment (FGA)
時間枠:Baseline, Week 10, Week 26, Week 36 (Control Group), and Week 52

The Functional Gait Assessment (FGA) is a 10-item scale that measures postural stability while individuals perform walking tasks that are scored from 0 to 3 (3 = normal, 2 = mild impairment, 1 = moderate impairment, 0 = severe impairment). Scores range from a minimum of 0 to a maximum of 30. Higher scores indicate better postural stability.

Baseline, Week 10, Week 26, Week 36 (Control Group), and Week 52
Patient-Specific Functional Scale (PSFS)
時間枠:Baseline, Week 5, Week 10, Week 18, Week 26, Week 31, Week 36, Week 41, Week 46, and Week 52

The PSFS asks patients to define up to five specific tasks that they have difficulty with or are unable to perform because of their physical injury or disability. Some research studies adapt the PSFS by asking participants to list three tasks rather than five, which is the plan for this study. The patients then rate their difficulty in performing those tasks on a scale of 0 to 10 with 0 meaning "unable to perform activity" to 10 meaning "able to perform activity at the same level as before injury or problem." The ratings for the three activities are averaged. Higher scores indicate greater ability to perform the activity.

Baseline, Week 5, Week 10, Week 18, Week 26, Week 31, Week 36, Week 41, Week 46, and Week 52
PROMIS® PROWalk
時間枠:Baseline, Week 5, Week 10, Week 18, Week 26, Week 31, Week 36, Week 41, Week 46, and Week 52

Eight items that have the most relevance for measuring change in individuals who have received Walkasins were selected from the 165 items comprising the PROMIS Item Bank v2.0 - Physical Function. Specifically, the selected items measure an individual's ability to perform various activities that involve upright mobility (balance, standing, and walking). Participants rate the eight items on a scale of 1 to 5; the raw scores are converted to T-scores for comparison to national norms.

Baseline, Week 5, Week 10, Week 18, Week 26, Week 31, Week 36, Week 41, Week 46, and Week 52

二次結果の測定

結果測定
メジャーの説明
時間枠
10-Meter Walk Test
時間枠:Baseline, Week 10, Week 26, Week 36 (Control Group), and Week 52

Gait speed will be measured through the 10-Meter Walk Test, timing only the middle 6 meters to allow for acceleration and deceleration. Participants will be instructed to walk at normal speed. Higher numbers indicate faster speeds (i.e., more meters per second).

Baseline, Week 10, Week 26, Week 36 (Control Group), and Week 52
Four-Stage Balance Test
時間枠:Baseline, Week 10, Week 26, Week 36 (Control Group), and Week 52

The 4-Stage Balance Test is part of the Centers for Disease Control's recommended test protocol for balance function. It includes four gradually more challenging postures the subject is exposed to: (1) Stand with feet side by side. (2) Stand with feet in semi-tandem stance. (3) Stand with feet in tandem stance. (4) Stand on one leg. Participants pass each level if they can hold the stance for 10 seconds and then move on to the next stance. If they cannot hold the stance, the test ends. Higher times indicate better balance than lower times.

Baseline, Week 10, Week 26, Week 36 (Control Group), and Week 52
Modified Multidirectional Reach Test
時間枠:Baseline, Week 10, Week 26, Week 36 (Control Group), Week 52

The Multidirectional Reach Test is a quick screening tool for fall risk to indirectly measure the limits of stability. The participant outstretches his/her arm to shoulder height next to a yardstick mounted on the wall; then he/she reaches as far as possible in the instructed direction without taking a step. The test administrator records the start and end position of the index finger of the outstretched hand, and the difference represents the total reach for that direction. Higher differences indicate better stability.

The Modified Multidirectional Reach Test used in this clinical trial will include only forward and backwards reaching that is completed and recorded with eyes closed. It will omit the left and right reaches.

Baseline, Week 10, Week 26, Week 36 (Control Group), Week 52
Single Leg Stance Test
時間枠:Baseline, Week 26

The Single Leg Stance Test (also called the unipedal stance test) "is a simple test for measuring static aspects of balance." It "is related to conditions such as peripheral neuropathy and intermittent claudication" and "is also associated with an increased risk for falls" (Spring et al., 2007) Participants stand unassisted on one leg with their hands on their hips. Timing begins when they lift one leg off the floor and ends when it touches the ground or the standing leg or an arm leaves the hips

Baseline, Week 26
Timed Up and Go (TUG) and Timed Up and Go Cognitive/Dual Task (TUG-COG)
時間枠:Baseline, Week 10, Week 26, Week 36 (Control Group), Week 52

The Timed Up and Go Test is part of the Centers for Disease Control (CDC)-recommended STEADI test protocol for balance function. From a seated position in a standard armchair, the participant is asked to stand up from the chair, walk to a line on the floor 10 feet away at normal pace, turn, walk back to the chair at normal pace, and sit down again. The tester records the time taken from the command "Go" until the subject sits down again. Lower times indicate better/faster performance.

The TUG-Cog is performed as described above; in addition, the participant is asked to count backwards by threes from a randomly selected number between 20 and 100. Lower times indicate better/faster performance.

Baseline, Week 10, Week 26, Week 36 (Control Group), Week 52
Activities-specific Balance Confidence Scale 6 (ABC-6)
時間枠:Baseline, Week 5, Week 10, Week 18, Week 26, Week 31, Week 36, Week 41, Week 46, and Week 52

Powell and Myers developed the 16-item Activities-specific Balance Confidence (ABC) Scale to detect levels of balance confidence in older adults. Schepens et al. (2009) validated a 6-item version of the ABC, using the six most challenging activities from the 16-item scale. The six tasks are rated on a scale of 0 to 100; a score of 0 indicates no confidence and a score of 100 indicates complete confidence when performing the task. The overall score is calculated by adding the individual items then dividing by the total number of items (6). The higher the score, the greater the person's balance confidence; thus, higher scores indicate that subjects are more confident of their balance.

Baseline, Week 5, Week 10, Week 18, Week 26, Week 31, Week 36, Week 41, Week 46, and Week 52
EuroQol HRQoL (EQ-5D-5L)
時間枠:Baseline, Week 10, Week 26, Week 36, and Week 52

The EQ-5D-5L consists of five questions, one each on "mobility," "self-care," "usual activities," "pain / discomfort," and "anxiety / depression." Participants rate themselves according to statements reflecting five levels ranging from no problems with the activity or construct to inability to perform the activity or having an extreme amount of difficulty with the construct.

Baseline, Week 10, Week 26, Week 36, and Week 52
PROMIS® Scale v2.0 - Pain Intensity 3a and Neuropathic Foot Pain Rating
時間枠:Baseline, Week 10, Week 26, Week 36, Week 52

The PROMIS Pain Intensity assessment measures "how much a person hurts" (https://www.healthmeasures.net/images/PROMIS/manuals/PROMIS_Pain_Intensity_Scoring_Manual.pdf). The three questions are not disease specific. Two items address pain experienced in the past seven days; the other, pain at present. In addition, we will ask participants to rate the neuropathic pain in their feet on scale of 0-10 (0 = No Pain, 10 = Worst Pain Imaginable).

Baseline, Week 10, Week 26, Week 36, Week 52
Rapid Assessment of Physical Activity (RAPA) and Telephone Assessment of Physical Activity (TAPA)
時間枠:Baseline, Week 10, Week 18, Week 26, Week 36, and Week 52

The Rapid Assessment of Physical Activity (RAPA) is a measure of physical activity, designed for use with older adults. The researchers will administer the RAPA during in-person visits and the TAPA, a telephone-based assessment of physical activity based on the RAPA, during the Weeks 18 and 36 telephone visits. The assessments consist of seven questions on light, moderate, and vigorous physical (aerobic) activities to which the participants respond "yes" or "no," depending on whether or not the question is true of them. Scoring is based on the number of the item to which the participants report the highest positive response (e.g., if the participant answered "Yes" to question 4 and "No" to 5, 6, and 7, then "4" is the participant's score). Higher scores indicate more physical activity. The final two items address strength and flexibility and are scored separately.

Baseline, Week 10, Week 18, Week 26, Week 36, and Week 52
Walkasins Experience Survey
時間枠:Baseline, Week 10, Week 26, Week 36 (Control Group), and Week 52

At the follow-up visits, the study team will ask the participants assigned to the Walkasins user group specific questions about their experience with Walkasins. Control group participants will complete the survey at Weeks 36 and 52.

Baseline, Week 10, Week 26, Week 36 (Control Group), and Week 52

その他の成果指標

結果測定
メジャーの説明
時間枠
Falls Monitoring
時間枠:Week 5, Week 10, Week 18, Week 26, Week 31, Week 36, Week 41, Week 46, and Week 52

Participants will report details regarding falls they experience during their enrollment in the study.

Week 5, Week 10, Week 18, Week 26, Week 31, Week 36, Week 41, Week 46, and Week 52
Monofilament Test
時間枠:Baseline, Week 26, and Week 52

The Centers for Medicare & Medicaid Services (CMS) identifies the monofilament test as the means of diagnosing loss of protective sensation (https://www.cms.gov/medicare-coverage-database/view/ncd.aspx?NCDId=171). To conduct the test, a clinician applies pressure with various sizes of monofilament to selected parts of the foot and asks the participant to indicate when he/she feels the filament. Including catch trials helps to ensure accurate test results. Per CMS, inability to feel a 10-gram monofilament on at least two of five test sites on either foot indicates loss of protective sensation (LOPS).

Baseline, Week 26, and Week 52
Vibration Test
時間枠:Baseline, Week 26, and Week 52

Vibration is one of several types of sensation encompassed within the somatosensory system, and it is often diminished in individuals with neuropathy. To examine vibration sense, a clinician applies a low-frequency (128 Hz) tuning fork to bony prominences and asks the participant (with closed eyes) to report when the vibration starts and stops. For this study, site personnel will employ the Rydel-Seiffer tuning fork, which provides a more quantitative assessment of vibratory sensation ranging from 2 to 8.

Baseline, Week 26, and Week 52

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

捜査官

  • スタディディレクター:Lars Oddsson, PhD、RxFunction Inc.

出版物と役立つリンク

研究に関する情報を入力する責任者は、自発的にこれらの出版物を提供します。これらは、研究に関連するあらゆるものに関するものである可能性があります。

一般刊行物

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2025年6月17日

一次修了 (推定)

2027年12月10日

研究の完了 (推定)

2028年6月1日

試験登録日

最初に提出

2025年4月28日

QC基準を満たした最初の提出物

2025年4月28日

最初の投稿 (実際)

2025年5月6日

学習記録の更新

投稿された最後の更新 (実際)

2026年10月5日

QC基準を満たした最後の更新が送信されました

2026年10月2日

最終確認日

2025年10月1日

詳しくは

本研究に関する用語

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

未定

IPD プランの説明

The sponsor will make a determination on data sharing prior to publication of the results.

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

はい

米国で製造され、米国から輸出された製品。

はい

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する